Roth Capital Downgrades China Cord Blood To Neutral

Roth Capital downgraded

from Buy to Neutral. The price target for China Cord Blood has been raised from $6.50 to $6.75. China Cord Blood shares have gained 15.69 percent over the past 52 weeks, while the S&P 500 index has surged 7.21 percent in the same period. China Cord Blood shares fell 0.16 percent to close at $6.33 yesterday.